Waiver confirms that paediatric studies of certepetide in pancreatic cancer are not needed Significant clinical trial burden and costs avoided due to waiver BASKING RIDGE, N.J., May 20, 2024 .
CEL-SCI Corporation today reported financial results for the quarter ended March 31, 2024, as well as key recent clinical and corporate developments.
Clinical and Corporate Developments.
Press release from Companies Publicerat: 2023-12-22 13:33:27 Cessatech A/S: Cessatech announces positive topline data from study 0205 with its lead candidate.